CANVAS - CANagliflozin cardioVascular Assessment Study
CANVAS
A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus
3 other identifiers
interventional
4,330
24 countries
301
Brief Summary
The study will assess canagliflozin (JNJ-28431754) in the treatment of patients with type 2 diabetes mellitus (T2DM) with regard to cardiovascular (CV) risk for major adverse cardiac events (MACE). Other objectives include evaluating the overall safety, tolerability, and effectiveness of canagliflozin. The data from this study will be combined with the data from CANVAS-R study (Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects with T2DM, NCT01989754) in a pre-specified integrated analysis of CV safety outcomes to satisfy US FDA post-marketing requirements for canagliflozin.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3 diabetes-mellitus-type-2
Started Dec 2009
Longer than P75 for phase_3 diabetes-mellitus-type-2
301 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 9, 2009
CompletedFirst Submitted
Initial submission to the registry
December 10, 2009
CompletedFirst Posted
Study publicly available on registry
December 15, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 22, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
February 22, 2017
CompletedResults Posted
Study results publicly available
December 7, 2018
CompletedDecember 7, 2018
November 1, 2018
7.2 years
December 10, 2009
August 24, 2018
November 5, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Major Adverse Cardiovascular Events (MACE) Composite of Cardiovascular (CV) Death, Non-Fatal Myocardial Infarction (MI), and Non-Fatal Stroke
MACE, defined as a composite of CV death, non-fatal MI, and nonfatal stroke. Adjudication of these events by the Endpoint Adjudication Committee (EAC) was performed in a blinded fashion. Event rate estimated based on the time to the first occurrence of MACE are presented.
Up to approximately 8 years
Secondary Outcomes (12)
Change From Baseline in Homeostasis Model Assessment 2 Steady-State Beta-Cell Function (HOMA2-%B) at the End-of-Treatment (EOT)
Baseline and end of treatment (approximately 338 weeks)
Percentage of Participants With Progression of Albuminuria at the End-of-Treatment
End of treatment (approximately 338 weeks)
Change From Baseline in Proinsulin/Insulin (PI/I) Ratio at the End-of-Treatment
Baseline and end of treatment (approximately 338 weeks)
Change From Baseline in Urinary Albumin/Creatinine Ratio at End-of-Treatment
Baseline and End of treatment (approximately 338 weeks)
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at End-of-Treatment
Baseline and end of treatment (approximately 338 weeks)
- +7 more secondary outcomes
Study Arms (3)
Placebo
PLACEBO COMPARATOREach patient will receive placebo (inactive medication) on background standard of care for diabetes once daily for the duration of the study
Canagliflozin (JNJ-28431754) 100 mg
EXPERIMENTALEach patient will receive canagliflozin (JNJ-28431754) 100 mg once daily on background standard of care for diabetes once daily for the duration of the study
Canagliflozin (JNJ-28431754) 300 mg
EXPERIMENTALEach patient will receive canagliflozin (JNJ-28431754) 300 mg once daily on background standard of care for diabetes once daily for the duration of the study
Interventions
One 100 mg capsule taken orally (by mouth) once daily
One 300 mg capsule taken orally (by mouth) once daily
Eligibility Criteria
You may qualify if:
- Patients must have a diagnosis of type 2 diabetes mellitus and greater than or equal to (\>=) 30 yrs old with history of cardiovascular (CV) event, or \>= 50 yrs old with high risk of CV events
- Patients must have inadequate diabetes control (as defined by glycosylated hemoglobin greater than or equal to 7.0% to less than or equal to 10.5% at screening) and be either (1) not currently on diabetes drug therapy or (2) on therapy with any approved class of diabetes drugs
You may not qualify if:
- A history of diabetic ketoacidosis, type 1 diabetes mellitus, pancreas or beta-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy
- History of one or more severe hypoglycemic (ie, very low blood sugar) episode within 6 months before screening
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (305)
Unknown Facility
Birmingham, Alabama, United States
Unknown Facility
Mesa, Arizona, United States
Unknown Facility
Tucson, Arizona, United States
Unknown Facility
La Mesa, California, United States
Unknown Facility
Los Gatos, California, United States
Unknown Facility
Pismo Beach, California, United States
Unknown Facility
Stockton, California, United States
Unknown Facility
Walnut Creek, California, United States
Unknown Facility
Doral, Florida, United States
Unknown Facility
Fort Lauderdale, Florida, United States
Unknown Facility
Jacksonville, Florida, United States
Unknown Facility
Miami, Florida, United States
Unknown Facility
Plantation, Florida, United States
Unknown Facility
Atlanta, Georgia, United States
Unknown Facility
Duluth, Georgia, United States
Unknown Facility
Boise, Idaho, United States
Unknown Facility
Eagle, Idaho, United States
Unknown Facility
Meridian, Idaho, United States
Unknown Facility
Peoria, Illinois, United States
Unknown Facility
Topeka, Kansas, United States
Unknown Facility
Crestview Hills, Kentucky, United States
Unknown Facility
Lexington, Kentucky, United States
Unknown Facility
Auburn, Maine, United States
Unknown Facility
Scarborough, Maine, United States
Unknown Facility
Oxon Hill, Maryland, United States
Unknown Facility
Royal Oak, Michigan, United States
Unknown Facility
Kansas City, Missouri, United States
Unknown Facility
St Louis, Missouri, United States
Unknown Facility
Omaha, Nebraska, United States
Unknown Facility
Camden, New Jersey, United States
Unknown Facility
Flushing, New York, United States
Unknown Facility
The Bronx, New York, United States
Unknown Facility
Chapel Hill, North Carolina, United States
Unknown Facility
Charlotte, North Carolina, United States
Unknown Facility
Cincinnati, Ohio, United States
Unknown Facility
Cleveland, Ohio, United States
Unknown Facility
Columbus, Ohio, United States
Unknown Facility
Gallipolis, Ohio, United States
Unknown Facility
Mentor, Ohio, United States
Unknown Facility
Toledo, Ohio, United States
Unknown Facility
Beaver, Pennsylvania, United States
Unknown Facility
Norristown, Pennsylvania, United States
Unknown Facility
Sayre, Pennsylvania, United States
Unknown Facility
Greenville, South Carolina, United States
Unknown Facility
Kingsport, Tennessee, United States
Unknown Facility
Dallas, Texas, United States
Unknown Facility
Houston, Texas, United States
Unknown Facility
Odessa, Texas, United States
Unknown Facility
San Antonio, Texas, United States
Unknown Facility
Temple, Texas, United States
Unknown Facility
Draper, Utah, United States
Unknown Facility
Salt Lake City, Utah, United States
Unknown Facility
Sandy City, Utah, United States
Unknown Facility
West Jordan, Utah, United States
Unknown Facility
Danville, Virginia, United States
Unknown Facility
Richmond, Virginia, United States
Unknown Facility
Spokane, Washington, United States
Unknown Facility
Tacoma, Washington, United States
Unknown Facility
Buenos Aires, Argentina
Unknown Facility
Capital Federal, Argentina
Unknown Facility
Ciudad Autonma Buenos Aires, Argentina
Unknown Facility
Corrientes, Argentina
Unknown Facility
Córdoba, Argentina
Unknown Facility
Godoy Cruz, Argentina
Unknown Facility
Mar del Plata, Argentina
Unknown Facility
Rosario, Argentina
Unknown Facility
Santa Fe, Argentina
Unknown Facility
Auchenflower, Australia
Unknown Facility
Box Hill, Australia
Unknown Facility
Caboolture, Australia
Unknown Facility
Caringbah, Australia
Unknown Facility
Clayton, Australia
Unknown Facility
Daw Park, Australia
Unknown Facility
East Ringwood, Australia
Unknown Facility
Elizabeth Vale, Australia
Unknown Facility
Hornsby, Nsw 2077, Australia
Unknown Facility
Kippa-Ring, Australia
Unknown Facility
Launceston, Australia
Unknown Facility
Liverpool, Australia
Unknown Facility
Melbourne, Australia
Unknown Facility
Milton, Australia
Unknown Facility
Parkville, Australia
Unknown Facility
Reservoir, Australia
Unknown Facility
Sherwood, Australia
Unknown Facility
Southport, Australia
Unknown Facility
St Leonards, Australia
Unknown Facility
West Heidelberg, Australia
Unknown Facility
Wollongong, Australia
Unknown Facility
Woolloongabba, Australia
Unknown Facility
Arlon, Belgium
Unknown Facility
Bonheiden, Belgium
Unknown Facility
Brussels, Belgium
Unknown Facility
Edegem, Belgium
Unknown Facility
Genk, Belgium
Unknown Facility
Leuven, Belgium
Unknown Facility
Calgary, Alberta, Canada
Unknown Facility
Coquitlam, British Columbia, Canada
Unknown Facility
Winnipeg, Manitoba, Canada
Unknown Facility
St. John's, Newfoundland and Labrador, Canada
Unknown Facility
Brampton, Ontario, Canada
Unknown Facility
Greater Sudbury, Ontario, Canada
Unknown Facility
London, Ontario, Canada
Unknown Facility
Mississauga, Ontario, Canada
Unknown Facility
Nemarket, Ontario, Canada
Unknown Facility
Sarnia, Ontario, Canada
Unknown Facility
Toronto, Ontario, Canada
Unknown Facility
Laval, Quebec, Canada
Unknown Facility
Lévis, Quebec, Canada
Unknown Facility
Montreal, Quebec, Canada
Unknown Facility
Val-Bélair, Quebec, Canada
Unknown Facility
Saskatoon, Saskatchewan, Canada
Unknown Facility
Bogotá, Colombia
Unknown Facility
Floridablanca, Colombia
Unknown Facility
Kralupy nad Vltavou, Czechia
Unknown Facility
Moravský Krumlov, Czechia
Unknown Facility
Olomouc, Czechia
Unknown Facility
Ostrava, Czechia
Unknown Facility
Písek, Czechia
Unknown Facility
Prague, Czechia
Unknown Facility
Znojmo, Czechia
Unknown Facility
Pärnu, Estonia
Unknown Facility
Tallinn, Estonia
Unknown Facility
Tartu, Estonia
Unknown Facility
Viljandi, Estonia
Unknown Facility
Amiens, France
Unknown Facility
Nîmes, France
Unknown Facility
Pessac, France
Unknown Facility
Berlin, Germany
Unknown Facility
Dortmund, Germany
Unknown Facility
Dresden, Germany
Unknown Facility
Hamburg, Germany
Unknown Facility
Künzing, Germany
Unknown Facility
Mainz, Germany
Unknown Facility
Münster, Germany
Unknown Facility
Pirna, Germany
Unknown Facility
Saarlouis, Germany
Unknown Facility
Speyer, Germany
Unknown Facility
Villingen-Schwenningen, Germany
Unknown Facility
Budapest, Hungary
Unknown Facility
Kecskemét, Hungary
Unknown Facility
Mosonmagyaróvár, Hungary
Unknown Facility
Zalaegerszeg, Hungary
Unknown Facility
Ahemadabad, India
Unknown Facility
Ahmedabad, India
Unknown Facility
Ambawadi, India
Unknown Facility
Bangalore, India
Unknown Facility
Bangalore, Karnataka, India
Unknown Facility
Belagavi, India
Unknown Facility
Calicut, India
Unknown Facility
Chennai, India
Unknown Facility
Coimbatore, India
Unknown Facility
Ernākulam, India
Unknown Facility
Ghaziabad, India
Unknown Facility
Hyderabad, India
Unknown Facility
Indore, India
Unknown Facility
Jaipur, India
Unknown Facility
Karnāl, India
Unknown Facility
Kerala, India
Unknown Facility
Kochi, India
Unknown Facility
Kolkata, India
Unknown Facility
Lucknow, India
Unknown Facility
Mangalore, India
Unknown Facility
Mumbai, India
Unknown Facility
Mysore, India
Unknown Facility
Nagpur, India
Unknown Facility
New Delhi, India
Unknown Facility
Patna, India
Unknown Facility
Pune, India
Unknown Facility
Rajkot, India
Unknown Facility
Trivandrum, Kerala, India
Unknown Facility
Vadodhara, India
Unknown Facility
Vijayawada, India
Unknown Facility
Visakhapatnam, India
Unknown Facility
Beersheba, Israel
Unknown Facility
Holon, Israel
Unknown Facility
Jerusalem, Israel
Unknown Facility
Kfar Saba, Israel
Unknown Facility
Luxembourg, Luxembourg
Unknown Facility
George Town, Malaysia
Unknown Facility
Johor Bahru, Malaysia
Unknown Facility
Kota Bharu, Malaysia
Unknown Facility
Kuala Lumpur, Malaysia
Unknown Facility
Petaling Jaya, Malaysia
Unknown Facility
Pulau Pinang, Malaysia
Unknown Facility
Subang Jaya, Malaysia
Unknown Facility
Aguascalientes, Mexico
Unknown Facility
Celaya, Mexico
Unknown Facility
Durango, Mexico
Unknown Facility
Guadalajara, Mexico
Unknown Facility
Mexico City, Mexico
Unknown Facility
Monterrey, Mexico
Unknown Facility
Almelo, Netherlands
Unknown Facility
Almere Stad, Netherlands
Unknown Facility
Amsterdam, Netherlands
Unknown Facility
Arnhem, Netherlands
Unknown Facility
Delft, Netherlands
Unknown Facility
Den Helder, Netherlands
Unknown Facility
Dordrecht, Netherlands
Unknown Facility
Eindhoven, Netherlands
Unknown Facility
Groningen, Netherlands
Unknown Facility
Hoorn, Netherlands
Unknown Facility
Rotterdam, Netherlands
Unknown Facility
Tilburg, Netherlands
Unknown Facility
Utrecht, Netherlands
Unknown Facility
Velp Gld, Netherlands
Unknown Facility
Zoetermeer, Netherlands
Unknown Facility
Zwijndrecht, Netherlands
Unknown Facility
Auckland, New Zealand
Unknown Facility
Christchurch, New Zealand
Unknown Facility
Dunedin, New Zealand
Unknown Facility
Tauranga, New Zealand
Unknown Facility
Wellington, New Zealand
Unknown Facility
Asker, Norway
Unknown Facility
Ålesund, Norway
Unknown Facility
Bekkestua, Norway
Unknown Facility
Elverum, Norway
Unknown Facility
Hamar, Norway
Unknown Facility
Lierskogen, Norway
Unknown Facility
Moss, Norway
Unknown Facility
Oslo, Norway
Unknown Facility
Skedsmokorset, Norway
Unknown Facility
Bialystok, Poland
Unknown Facility
Ciechocinek, Poland
Unknown Facility
Gniewkowo, Poland
Unknown Facility
Grudziądz, Poland
Unknown Facility
Katowice, Poland
Unknown Facility
Krakow, Poland
Unknown Facility
Lublin, Poland
Unknown Facility
Poznan, Poland
Unknown Facility
Płock, Poland
Unknown Facility
Rzeszów, Poland
Unknown Facility
Sławków, Poland
Unknown Facility
Torun, Poland
Unknown Facility
Warsaw, Poland
Unknown Facility
Wroclaw, Poland
Unknown Facility
Arkhangelsk, Russia
Unknown Facility
Chelyabinsk, Russia
Unknown Facility
Kemerovo, Russia
Unknown Facility
Kirov, Russia
Unknown Facility
Kursk, Russia
Unknown Facility
Moscow, Russia
Unknown Facility
Nizhny Novgorod, Russia
Unknown Facility
Novosibirsk, Russia
Unknown Facility
Omsk, Russia
Unknown Facility
Penza, Russia
Unknown Facility
Rostov-on-Don, Russia
Unknown Facility
Russia, Russia
Unknown Facility
Ryazan, Russia
Unknown Facility
Saint Petersburg, Russia
Unknown Facility
Saratov, Russia
Unknown Facility
Smolensk, Russia
Unknown Facility
Tomsk, Russia
Unknown Facility
Tula, Russia
Unknown Facility
Tyumen, Russia
Unknown Facility
Yaroslavl, Russia
Unknown Facility
Yaroslavl Nap, Russia
Unknown Facility
Yekaterinburg, Russia
Unknown Facility
Alicante, Spain
Unknown Facility
Almería, Spain
Unknown Facility
Barcelona, Spain
Unknown Facility
Figueres, Spain
Unknown Facility
Madrid, Spain
Unknown Facility
Málaga, Spain
Unknown Facility
Oviedo, Spain
Unknown Facility
Reus, Spain
Unknown Facility
Sabadell, Spain
Unknown Facility
Sant Joan d'Alacant, Spain
Unknown Facility
Santiago de Compostela, Spain
Unknown Facility
Seville, Spain
Unknown Facility
Valencia, Spain
Unknown Facility
Viladecans, Spain
Unknown Facility
Borås, Sweden
Unknown Facility
Gothenburg, Sweden
Unknown Facility
Helsingborg, Sweden
Unknown Facility
Lund, Sweden
Unknown Facility
Malmo, Sweden
Unknown Facility
Oskarshamn, Sweden
Unknown Facility
Piteå, Sweden
Unknown Facility
Stockholm, Sweden
Unknown Facility
Uddevalla, Sweden
Unknown Facility
Dnipro, Ukraine
Unknown Facility
Donetsk, Ukraine
Unknown Facility
Kharkiv, Ukraine
Unknown Facility
Kiev, Ukraine
Unknown Facility
Kyiv, Ukraine
Unknown Facility
Odesa, Ukraine
Unknown Facility
Ternopil, Ukraine
Unknown Facility
Uzhhorod, Ukraine
Unknown Facility
Vinnitsa, Ukraine
Unknown Facility
Zaporizhzhya, Ukraine
Unknown Facility
Belfast, United Kingdom
Unknown Facility
Blackburn, United Kingdom
Unknown Facility
Bolton, United Kingdom
Unknown Facility
Chorley, United Kingdom
Unknown Facility
Derby, United Kingdom
Unknown Facility
Glasgow, United Kingdom
Unknown Facility
Hull, United Kingdom
Unknown Facility
Leicester, United Kingdom
Unknown Facility
Liverpool, United Kingdom
Unknown Facility
London, United Kingdom
Unknown Facility
Londonderry, United Kingdom
Unknown Facility
Manchester, United Kingdom
Unknown Facility
Randalstown, United Kingdom
Unknown Facility
Salford, United Kingdom
Unknown Facility
York, United Kingdom
Related Publications (43)
Mottl A, Scott C, Green JB, Heerspink HJL, Mann JFE, McGill JB, Nangaku M, Rosenstock J, Rossing P, Li L, Li N, Vaduganathan M, Agarwal R; CONFIDENCE Trial Investigators. Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial. J Am Soc Nephrol. 2025 Nov 6. doi: 10.1681/ASN.0000000928. Online ahead of print. No abstract available.
PMID: 41196655DERIVEDBayes-Genis A, Cai A, Liu Y, Pandey A, Pop-Busui R, Hansen M, Januzzi JL. Impact of canagliflozin on heart stress and outcomes: Pooled insights from CREDENCE and CANVAS. Eur J Heart Fail. 2025 Dec;27(12):2887-2896. doi: 10.1002/ejhf.3786. Epub 2025 Jul 21.
PMID: 40689549DERIVEDDoi Y, Hamano T, Yamaguchi O, Isaka Y. Canagliflozin may increase thromboembolic events in males with erythrocytosis but not in females. Blood Adv. 2025 Jul 8;9(13):3202-3212. doi: 10.1182/bloodadvances.2025016320.
PMID: 40239057DERIVEDNguyen TN, Yu J, Perkovic V, Jardine M, Mahaffey KW, Chow CK, Arnott C, Lindley RI. The Efficacy and Safety of Canagliflozin by Frailty Status in Participants of the CANVAS and CREDENCE Trials. J Am Geriatr Soc. 2025 Jun;73(6):1787-1796. doi: 10.1111/jgs.19444. Epub 2025 Mar 19.
PMID: 40105285DERIVEDChatur S, Vaduganathan M, Fletcher RA, Perkovic V, Heerspink H, Arnott C, Pollock C, Mahaffey KW, Neal B, Jardine M, Solomon SD, Neuen BL. Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant-level pooled analysis of the CANVAS and CREDENCE trials. Eur J Heart Fail. 2025 Jun;27(6):994-1002. doi: 10.1002/ejhf.3586. Epub 2025 Jan 23.
PMID: 39844714DERIVEDVaduganathan M, Cannon CP, Jardine MJ, Heerspink HJL, Arnott C, Neuen BL, Sarraju A, Gogate J, Seufert J, Neal B, Perkovic V, Mahaffey KW, Kosiborod MN. Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trial. Eur J Heart Fail. 2024 Sep;26(9):1967-1975. doi: 10.1002/ejhf.3292. Epub 2024 Jun 26.
PMID: 38932575DERIVEDNatale P, Tunnicliffe DJ, Toyama T, Palmer SC, Saglimbene VM, Ruospo M, Gargano L, Stallone G, Gesualdo L, Strippoli GF. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes. Cochrane Database Syst Rev. 2024 May 21;5(5):CD015588. doi: 10.1002/14651858.CD015588.pub2.
PMID: 38770818DERIVEDSharma A, Razaghizad A, Joury A, Levin A, Bajaj HS, Mancini GBJ, Wong NC, Slee A, Ang FG, Rapattoni W, Neuen BL, Arnott C, Perkovic V, Mahaffey KW. Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial. J Am Heart Assoc. 2024 Feb 6;13(3):e031586. doi: 10.1161/JAHA.123.031586. Epub 2024 Jan 19.
PMID: 38240199DERIVEDYu J, Sweeting AN, Gianacas C, Houston L, Lee V, Fletcher RA, Perkovic V, Li Q, Neuen BL, Berwanger O, Heerspink HJL, de Zeeuw D, Arnott C. The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial. Diabetes Obes Metab. 2023 Dec;25(12):3724-3735. doi: 10.1111/dom.15267. Epub 2023 Sep 6.
PMID: 37671609DERIVEDSen T, Ju W, Nair V, Ladd P, Menon R, Otto EA, Pyle L, Vigers T, Nelson RG, Arnott C, Neal B, Hansen MK, Kretzler M, Bjornstad P, Heerspink HJL. Sodium glucose co-transporter 2 inhibition increases epidermal growth factor expression and improves outcomes in patients with type 2 diabetes. Kidney Int. 2023 Oct;104(4):828-839. doi: 10.1016/j.kint.2023.07.007. Epub 2023 Aug 4.
PMID: 37543256DERIVEDFletcher RA, Arnott C, Rockenschaub P, Schutte AE, Carpenter L, Vaduganathan M, Agarwal R, Bakris G, Chang TI, Heerspink HJL, Jardine MJ, Mahaffey KW, Neal B, Pollock C, Jun M, Rodgers A, Perkovic V, Neuen BL. Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials. J Am Heart Assoc. 2023 Jul 4;12(13):e028516. doi: 10.1161/JAHA.122.028516. Epub 2023 Jun 22.
PMID: 37345834DERIVEDBorisov AN, Kutz A, Christ ER, Heim MH, Ebrahimi F. Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients With Diabetes Mellitus: New Insights From CANVAS. J Clin Endocrinol Metab. 2023 Oct 18;108(11):2940-2949. doi: 10.1210/clinem/dgad249.
PMID: 37149821DERIVEDFerrannini G, Pollock C, Natali A, Yavin Y, Mahaffey KW, Ferrannini E. Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCE. Cardiovasc Diabetol. 2023 Apr 29;22(1):100. doi: 10.1186/s12933-023-01832-5.
PMID: 37120538DERIVEDRasmussen DGK, Hansen MK, Blair J, Jatkoe TA, Neal B, Karsdal MA, Genovese F. Endotrophin is a risk marker of complications in CANagliflozin cardioVascular Assessment Study (CANVAS): a randomized controlled trial. Cardiovasc Diabetol. 2022 Nov 28;21(1):261. doi: 10.1186/s12933-022-01666-7.
PMID: 36443792DERIVEDNunes JC, Yu J, Arnott C, Jardine MJ, Perkovic V, Mahaffey KW. Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program. Diabetes Obes Metab. 2022 Dec;24(12):2459-2464. doi: 10.1111/dom.14832. Epub 2022 Aug 19. No abstract available.
PMID: 35938182DERIVEDFerrannini E, Baldi S, Scozzaro T, Tsimihodimos V, Tesfaye F, Shaw W, Rosenthal N, Figtree GA, Neal B, Mahaffey KW, Perkovic V, Hansen MK. Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS). Diabetes Care. 2022 Aug 1;45(8):1893-1899. doi: 10.2337/dc21-2398.
PMID: 35724306DERIVEDVaduganathan M, Sattar N, Xu J, Butler J, Mahaffey KW, Neal B, Shaw W, Rosenthal N, Pfeifer M, Hansen MK, Januzzi JL Jr. Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin. J Am Coll Cardiol. 2022 Feb 8;79(5):432-444. doi: 10.1016/j.jacc.2021.11.027.
PMID: 35115099DERIVEDWaijer SW, Sen T, Arnott C, Neal B, Kosterink JGW, Mahaffey KW, Parikh CR, de Zeeuw D, Perkovic V, Neuen BL, Coca SG, Hansen MK, Gansevoort RT, Heerspink HJL. Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease. Clin J Am Soc Nephrol. 2022 Feb;17(2):251-259. doi: 10.2215/CJN.08780621. Epub 2021 Dec 7.
PMID: 34876454DERIVEDYoung TK, Li JW, Kang A, Heerspink HJL, Hockham C, Arnott C, Neuen BL, Zoungas S, Mahaffey KW, Perkovic V, de Zeeuw D, Fulcher G, Neal B, Jardine M. Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program. Diabetologia. 2021 Nov;64(11):2402-2414. doi: 10.1007/s00125-021-05524-1. Epub 2021 Aug 26.
PMID: 34448033DERIVEDYu J, Li J, Leaver PJ, Arnott C, Huffman MD, Udell JA, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Matthews DR, Shaw W, Rosenthal N, Neal B, Figtree GA. Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial. Cardiovasc Res. 2022 Mar 16;118(4):1103-1114. doi: 10.1093/cvr/cvab128.
PMID: 33826709DERIVEDYu J, Arnott C, Neuen BL, Heersprink HL, Mahaffey KW, Cannon CP, Khan SS, Baldridge AS, Shah SJ, Huang Y, Li C, Figtree GA, Perkovic V, Jardine MJ, Neal B, Huffman MD. Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program. ESC Heart Fail. 2021 Apr;8(2):1482-1493. doi: 10.1002/ehf2.13236. Epub 2021 Feb 17.
PMID: 33595905DERIVEDJanuzzi JL Jr, Butler J, Sattar N, Xu J, Shaw W, Rosenthal N, Pfeifer M, Mahaffey KW, Neal B, Hansen MK. Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study. Diabetes Care. 2021 Jan;44(1):210-216. doi: 10.2337/dc20-1889. Epub 2020 Nov 6.
PMID: 33158949DERIVEDJanuzzi JL Jr, Xu J, Li J, Shaw W, Oh R, Pfeifer M, Butler J, Sattar N, Mahaffey KW, Neal B, Hansen MK. Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction. J Am Coll Cardiol. 2020 Nov 3;76(18):2076-2085. doi: 10.1016/j.jacc.2020.09.004.
PMID: 33121714DERIVEDNeuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, Fulcher G, Blais J, Li Q, Jardine MJ, Perkovic V, Wheeler DC. Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program. Am J Kidney Dis. 2021 Jan;77(1):23-34.e1. doi: 10.1053/j.ajkd.2020.06.018. Epub 2020 Sep 21.
PMID: 32971190DERIVEDOshima M, Neal B, Toyama T, Ohkuma T, Li Q, de Zeeuw D, Heerspink HJL, Mahaffey KW, Fulcher G, Canovatchel W, Matthews DR, Perkovic V. Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program. J Am Soc Nephrol. 2020 Oct;31(10):2446-2456. doi: 10.1681/ASN.2019121312. Epub 2020 Jul 21.
PMID: 32694216DERIVEDMatthews DR, Wysham C, Davies M, Slee A, Alba M, Lee M, Perkovic V, Mahaffey KW, Neal B. Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program. Diabetes Obes Metab. 2020 Nov;22(11):2199-2203. doi: 10.1111/dom.14143. Epub 2020 Aug 24.
PMID: 32691499DERIVEDZhou Z, Jardine M, Perkovic V, Matthews DR, Mahaffey KW, de Zeeuw D, Fulcher G, Desai M, Oh R, Simpson R, Watts NB, Neal B. Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program. Diabetologia. 2019 Oct;62(10):1854-1867. doi: 10.1007/s00125-019-4955-5. Epub 2019 Aug 10.
PMID: 31399845DERIVEDFigtree GA, Radholm K, Barrett TD, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Matthews DR, Shaw W, Neal B. Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus. Circulation. 2019 May 28;139(22):2591-2593. doi: 10.1161/CIRCULATIONAHA.119.040057. Epub 2019 Mar 17. No abstract available.
PMID: 30882240DERIVEDZhou Z, Lindley RI, Radholm K, Jenkins B, Watson J, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Shaw W, Oh R, Desai M, Matthews DR, Neal B. Canagliflozin and Stroke in Type 2 Diabetes Mellitus. Stroke. 2019 Feb;50(2):396-404. doi: 10.1161/STROKEAHA.118.023009.
PMID: 30591006DERIVEDNeuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, Fulcher G, Desai M, Li Q, Deng H, Rosenthal N, Jardine MJ, Bakris G, Perkovic V. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. Circulation. 2018 Oct 9;138(15):1537-1550. doi: 10.1161/CIRCULATIONAHA.118.035901.
PMID: 29941478DERIVEDPerkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, Barrett TD, Weidner-Wells M, Deng H, Matthews DR, Neal B. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018 Sep;6(9):691-704. doi: 10.1016/S2213-8587(18)30141-4. Epub 2018 Jun 21.
PMID: 29937267DERIVEDWittbrodt ET, Eudicone JM, Bell KF, Enhoffer DM, Latham K, Green JB. Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population. Am J Manag Care. 2018 Apr;24(8 Suppl):S138-S145.
PMID: 29693360DERIVEDRadholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW, de Zeeuw D, Fulcher G, Barrett TD, Shaw W, Desai M, Matthews DR, Neal B. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program. Circulation. 2018 Jul 31;138(5):458-468. doi: 10.1161/CIRCULATIONAHA.118.034222.
PMID: 29526832DERIVEDMahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018 Jan 23;137(4):323-334. doi: 10.1161/CIRCULATIONAHA.117.032038. Epub 2017 Nov 13.
PMID: 29133604DERIVEDYale JF, Xie J, Sherman SE, Garceau C. Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus. Clin Ther. 2017 Nov;39(11):2230-2242.e2. doi: 10.1016/j.clinthera.2017.10.003. Epub 2017 Nov 3.
PMID: 29103664DERIVEDNeal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.
PMID: 28605608DERIVEDWatts NB, Bilezikian JP, Usiskin K, Edwards R, Desai M, Law G, Meininger G. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2016 Jan;101(1):157-66. doi: 10.1210/jc.2015-3167. Epub 2015 Nov 18.
PMID: 26580237DERIVEDGavin JR 3rd, Davies MJ, Davies M, Vijapurkar U, Alba M, Meininger G. The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2015;31(9):1693-702. doi: 10.1185/03007995.2015.1067192. Epub 2015 Sep 4.
PMID: 26121561DERIVEDFulcher G, Matthews DR, Perkovic V, de Zeeuw D, Mahaffey KW, Weiss R, Rosenstock J, Capuano G, Desai M, Shaw W, Vercruysse F, Meininger G, Neal B. Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial. Diabetes Ther. 2015 Sep;6(3):289-302. doi: 10.1007/s13300-015-0117-z. Epub 2015 Jun 17.
PMID: 26081793DERIVEDNeal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Ways K, Desai M, Shaw W, Capuano G, Alba M, Jiang J, Vercruysse F, Meininger G, Matthews D; CANVAS Trial Collaborative Group. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care. 2015 Mar;38(3):403-11. doi: 10.2337/dc14-1237. Epub 2014 Dec 2.
PMID: 25468945DERIVEDWeir MR, Kline I, Xie J, Edwards R, Usiskin K. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin. 2014 Sep;30(9):1759-68. doi: 10.1185/03007995.2014.919907. Epub 2014 May 22.
PMID: 24786834DERIVEDNyirjesy P, Sobel JD, Fung A, Mayer C, Capuano G, Ways K, Usiskin K. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin. 2014 Jun;30(6):1109-19. doi: 10.1185/03007995.2014.890925. Epub 2014 Feb 21.
PMID: 24517339DERIVEDNeal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Stein P, Desai M, Shaw W, Jiang J, Vercruysse F, Meininger G, Matthews D. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. Am Heart J. 2013 Aug;166(2):217-223.e11. doi: 10.1016/j.ahj.2013.05.007. Epub 2013 Jun 24.
PMID: 23895803DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Senior Director Clinical Leader
- Organization
- Janssen- Cilag International NV
Study Officials
- STUDY DIRECTOR
Janssen Research & Development, LLC Clinical Trial
Janssen Research & Development, LLC
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 10, 2009
First Posted
December 15, 2009
Study Start
December 9, 2009
Primary Completion
February 22, 2017
Study Completion
February 22, 2017
Last Updated
December 7, 2018
Results First Posted
December 7, 2018
Record last verified: 2018-11